Related Experiment Video
Updated: Dec 17, 2025
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications
Johann S Bergholz1,2,3, Qiwei Wang4,2, Sheheryar Kabraji4,5
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. jean_zhao@dfci.harvard.edu johann_bergholz@dfci.harvard.edu.
Abstract:
Small-molecule targeted therapies have demonstrated outstanding potential in the clinic. These drugs are designed to minimize adverse effects by selectively attacking cancer cells while exerting minimal damage to normal cells. Although initial response to targeted therapies may be high, yielding positive response rates and often improving survival for an important percentage of patients, resistance often limits long-term effectiveness. On the other hand, immunotherapy has demonstrated durable results, yet for a limited number of patients. Growing evidence indicates that some targeted agents can modulate different components of the antitumor immune response. These include immune sensitization by inhibiting tumor cell-intrinsic immune evasion programs or enhancing antigenicity, as well as direct effects on immune effector and immunosuppressive cells. The combination of these two approaches, therefore, has the potential to result in synergistic and durable outcomes for patients. In this review, we focus on the latest advances on integrating immunotherapy with small-molecule targeted inhibitors. In particular, we discuss how specific oncogenic events differentially affect immune response, and the implications of these findings on the rational design of effective combinations of immunotherapy and targeted therapies.
Insights
Combining targeted cancer therapies with immunotherapy shows promise for durable patient outcomes. This approach leverages targeted agents to enhance the immune system
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Small-molecule targeted therapies offer selective cancer cell attack with fewer side effects.
- While effective initially, targeted therapies often face resistance, limiting long-term benefits.
- Immunotherapy provides durable responses but benefits a limited patient group.
Purpose of the Study:
- To review recent advances in integrating immunotherapy with small-molecule targeted inhibitors.
- To explore how oncogenic events influence antitumor immune responses.
- To guide the rational design of combination therapies for improved patient outcomes.
Main Methods:
- Literature review focusing on the interplay between targeted therapies and the immune system.
- Analysis of how targeted agents modulate immune sensitization, antigenicity, and immune cell function.
- Discussion of oncogenic event-specific immune modulation and its impact on combination strategies.
Main Results:
- Targeted therapies can enhance antitumor immunity by overcoming immune evasion and increasing antigenicity.
- Specific oncogenic events differentially impact immune responses, informing combination therapy design.
- Combining targeted agents with immunotherapy has the potential for synergistic and durable antitumor effects.
Conclusions:
- Integrating targeted therapies and immunotherapy offers a promising strategy for overcoming resistance and improving durable responses.
- Understanding the molecular basis of immune modulation by targeted agents is crucial for rational combination therapy development.
- This integrated approach holds significant potential for enhancing patient survival and treatment efficacy in oncology.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...